

**Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]**

Market Report | 2022-11-18 | 197 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

**Report description:**

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The glycomic therapeutics market in the Middle East & Africa is expected to grow from US\$ 5.79 billion in 2022 to US\$ 12.85 billion by 2028; it is estimated to grow at a CAGR of 13.1% from 2022 to 2028.

#### New Tools in Glycomics Research to Drive Market Growth

Glycomics has the potential to pave the way for innovative treatment approaches by enhancing the characterization of molecules crucial for the development of diseases. It can be a substantial addition to technologies used in genomics and proteomics. Comparative glycomics will be essential for identifying the glycans that cause the disease. There is a rising number of studies that will provide vital information on the relationship between clinical outcomes and glycomic anomalies. Immunohistochemistry (IHC), Liquid Chromatography-Mass Spectrometry (LC-MS), and high-throughput fluorescence flow cytometry have been used to distinguish cell populations using glycoproteins. These are among the important technologies utilized to advance glycomics. LC-MS can provide structural details about glycoconjugates by separating several glycoprotein isoforms from a single protein species. Unbiased surveys of cellular proteomes are now available due to high-throughput MS-based proteomics, and the method is swiftly applied to glycomics.

Structural reference databases are quickly emerging to close the gap between the variety and complexity of glycan structures. Identification of disease-related glycoconjugates by LC-MS, which employs antibody-based capture to view glycoconjugate expression with cell-staining or fluorescence, can be used to assess or validate IHC. Targeting complete cells rather than tissue fragments, immunocytochemistry (ICC) reveals glycoprotein expression patterns at the cellular level utilizing the same imaging techniques as IHC. It will be possible to witness new aspects of glycomics, such as thorough characterization of metabolic junctions and pathways, by modifying IHC and ICC to concentrate on additional glycoconjugates, including glycolipids. Tandem or multi-technology procedures, such as MS-IHC, would provide the analytical ability to labs to handle the glycoconjugates complexity and improve glycoconjugate diagnosis. The clinical applications of glycomics are catching up to those of genomics and proteomics due to the development of new high-throughput methods to study the structure and expression of glycans and ongoing innovation in glycan biomarkers and therapies. Integrating glycomics will revolutionize precision medicine into an extensive omics strategy, providing new information on the interactions between genes, proteins, and glycans. The combination of omics data with digital health platforms has the potential to improve clinical trials and provides knowledge to researchers and doctors regarding illness. Owing to the rising scientific discoveries, widespread acceptance of glycomics and personalized medicine will necessitate significant changes in regulatory and reimbursement procedures and legislative privacy laws. Thus, customized healthcare challenges will be met and overcome with the assurance that the research behind glycomic therapeutics is adequate and that the practice of medicine is evidence-based.

Growing evidence of glycomics role in human health highlights the need to integrate glycomics into precision medicine. Cell surface expression of glycoconjugates determines in vivo recognition and in vitro interactions. Microorganisms that perform important functions for their hosts, such as food digestion and vitamin synthesis and absorption, utilize complex carbohydrates to tell immune cells that they are not harmful. Pathogens that cause deadly diseases, such as tuberculosis and malaria, use similar strategies to evade attacks by the immune system.

#### Market Overview

The UAE, Saudi Arabia, and South Africa are the three major countries in the Middle East & South Africa. Saudi Arabia was the largest market for glycomic therapeutics in this region in 2022. The market for glycomic therapeutics in the Middle East & Africa is anticipated to grow at a CAGR of 14.2% during the forecast period; this growth is attributed to the rising prevalence of cancer and metabolic diseases and increasing government initiatives in terms of funding and healthcare-related policies.

#### Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028 (US\$ Billion)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The Middle East & Africa glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the Middle East & Africa glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Middle East & Africa glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Middle East & Africa glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher's disease, MPS-1 & IV, cancer, alzheimer's disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Middle East & Africa glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Middle East & Africa glycomic therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022. Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Bayer AG; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in the Middle East & Africa.

### Table of Contents:

#### TABLE OF CONTENTS

1. Introduction
  - 1.1 Study Scope
  - 1.2 The Insight Partners Research Report Guidance
  - 1.3 Market Segmentation
    - 1.3.1 Middle East & Africa Glycomic Therapeutics Market - By Class
    - 1.3.2 Middle East & Africa Glycomic Therapeutics Market - By Structures
    - 1.3.3 Middle East & Africa Glycomic Therapeutics Market - By Indications
    - 1.3.4 Middle East & Africa Glycomic Therapeutics Market - By Mode of Action
    - 1.3.5 Middle East & Africa Glycomic Therapeutics Market - By Country
2. Middle East & Africa Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
  - 3.1 Coverage
  - 3.2 Secondary Research
  - 3.3 Primary Research
4. Middle East & Africa Glycomic Therapeutics Market - Market Landscape
  - 4.1 Overview
  - 4.2 PEST Analysis
    - 4.2.1 Middle East & Africa - PEST Analysis
  - 4.3 Expert Opinion
5. Middle East & Africa Glycomic Therapeutics Market - Key Market Dynamics
  - 5.1 Market Drivers
    - 5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
    - 5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

5.2 Market Restraints	
5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.	
5.3 Market Opportunities	
5.3.1 Wide Applications of Glycomics in Therapeutics	
5.4 Future Trends	
5.4.1 New Tools in Glycomics Research	
5.5 Impact Analysis	
6. Glycomic Therapeutics Market- Middle East & Africa Analysis	
6.1 Middle East & Africa Glycomic Therapeutics Market Revenue Forecast and Analysis	
6.1.1 Middle East & Africa : Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US\$ Million)	
7. Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class	
7.1 Overview	
7.2 Middle East & Africa Glycomic Therapeutics Market, By Class 2022 & 2028 (%)	
7.2.1 Middle East & Africa: Glycomic Therapeutics Market, by Class, 2019-2028 (US\$ Million)	
7.3 Isolated	
7.3.1 Overview	
7.3.2 Middle East & Africa Isolated Revenue and Forecast to 2028 (US\$ Million)	
7.4 Synthetic	
7.4.1 Overview	
7.4.2 Middle East & Africa Synthetic - Revenue and Forecast to 2028 (US\$ Million)	
8. Middle East & Africa Glycomics Therapeutics Market Analysis and Forecasts To 2028 - By Indication	
8.1 Overview	
8.2 Middle East & Africa Glycomics Market, By Indication 2022 & 2028 (%)	
8.2.1 Middle East & Africa: Glycomic Therapeutics Market, by Indication, 2019-2028 (US\$ Million)	
8.3 Thrombosis and Chemoprophylaxis	
8.3.1 Overview	
8.3.2 Middle East & Africa Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US\$ Million)	
8.4 Anaemia	
8.4.1 Overview	
8.4.2 Middle East & Africa Anaemia Revenue and Forecast to 2028 (US\$ Million)	
8.5 Anti-adhesive and Anti-inflammatory	
8.5.1 Overview	
8.5.2 Middle East & Africa Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US\$ Million)	
8.6 Cataract	
8.6.1 Overview	
8.6.2 Middle East & Africa Cataract Revenue and Forecast to 2028 (US\$ Million)	
8.7 Gaucher's diseases	
8.7.1 Overview	
8.7.2 Middle East & Africa Gaucher's diseases Revenue and Forecast to 2028 (US\$ Million)	
8.8 MPS-1 & IV	
8.8.1 Overview	
8.8.2 Middle East & Africa MPS-1 & IV Revenue and Forecast to 2028 (US\$ Million)	
8.9 Cancer	
8.9.1 Overview	
8.9.2 Middle East & Africa Cancer Revenue and Forecast to 2028 (US\$ Million)	
8.10 Alzheimer's	
8.10.1 Overview	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.10.2 Middle East & Africa Alzheimer's Revenue and Forecast to 2028 (US\$ Million)
- 8.11 Influenza Type A and B
  - 8.11.1 Overview
  - 8.11.2 Middle East & Africa Influenza Type A and B Revenue and Forecast to 2028 (US\$ Million)
- 8.12 Others
  - 8.12.1 Overview
  - 8.12.2 Middle East & Africa Others Revenue and Forecast to 2028 (US\$ Million)
- 9. Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Structures
  - 9.1 Overview
  - 9.2 Middle East & Africa Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
    - 9.2.1 Middle East & Africa: Glycomic Therapeutics Market, by Structure, 2019-2028 (US\$ Million)
      - 9.2.1.1 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US\$ Million)
      - 9.2.1.2 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US\$ Million)
      - 9.2.1.3 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US\$ Million)
      - 9.2.1.4 Middle East & Africa: Glycomic Therapeutics Market, by Others, 2019-2028 (US\$ Million)
  - 9.3 Glycoproteins
    - 9.3.1 Overview
    - 9.3.2 Middle East & Africa Glycoproteins - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.4 Targeting Sialic Acid
    - 9.4.1 Overview
    - 9.4.2 Middle East & Africa Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.4.3 Zanamivir
      - 9.4.3.1 Overview
      - 9.4.3.2 Middle East & Africa Zanamivir - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.4.4 Oseltamivir
      - 9.4.4.1 Overview
      - 9.4.4.2 Middle East & Africa Oseltamivir - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.5 Proteoglycans
    - 9.5.1 Overview
    - 9.5.2 Middle East & Africa Proteoglycans - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans
    - 9.6.1 Overview
    - 9.6.2 Middle East & Africa Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.7 Targeting Glycosaminoglycans
    - 9.7.1 Overview
    - 9.7.2 Middle East & Africa Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.7.3 Heparin
      - 9.7.3.1 Overview
      - 9.7.3.2 Middle East & Africa Heparin - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.7.4 Hyaluronan (HA)
      - 9.7.4.1 Overview
      - 9.7.4.2 Middle East & Africa Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.7.5 Laronidase
      - 9.7.5.1 Overview
      - 9.7.5.2 Middle East & Africa Laronidase - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.7.6 Galsulfase (Naglazyme)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

9.7.6.1 Overview	
9.7.6.2 Middle East & Africa Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US\$ Million)	
9.7.7 Hyaluronidase (Cumulase)	
9.7.7.1 Overview	
9.7.7.2 Middle East & Africa Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US\$ Million)	
9.7.8 Others	
9.7.8.1 Overview	
9.7.8.2 Middle East & Africa Others - Market Revenue and Forecast to 2028 (US\$ Million)	
9.8 Targeting Glycosphingolipids	
9.8.1 Overview	
9.8.2 Middle East & Africa Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US\$ Million)	
9.8.3 Imiglucerase (Cerezyme)	
9.8.3.1 Overview	
9.8.3.2 Middle East & Africa Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US\$ Million)	
9.8.3.3 Agalsidase (Fabrazyme)	
9.8.3.3.1 Overview	
9.8.3.3.2 Middle East & Africa Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US\$ Million)	
9.8.3.4 N-butyl-deoxynojirimycin (DNJ)	
9.8.3.4.1 Overview	
9.8.3.4.2 Middle East & Africa N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US\$ Million)	
9.8.4 Others	
9.8.4.1 Overview	
9.8.4.2 Middle East & Africa Others - Market Revenue and Forecast to 2028 (US\$ Million)	
9.9 Others	
9.9.1 Overview	
9.9.2 Middle East & Africa Others - Market Revenue and Forecast to 2028 (US\$ Million)	
9.9.3 Acarbose	
9.9.3.1 Overview	
9.9.3.2 Middle East & Africa Acarbose - Market Revenue and Forecast to 2028 (US\$ Million)	
9.9.3.3 Alglucosidase Alfa (Myozyme)	
9.9.3.3.1 Overview	
9.9.3.3.2 Middle East & Africa Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US\$ Million)	
9.9.3.4 Allosamidin	
9.9.3.4.1 Overview	
9.9.3.4.2 Middle East & Africa Allosamidin - Market Revenue and Forecast to 2028 (US\$ Million)	
9.9.4 Others	
9.9.4.1 Overview	
9.9.4.2 Middle East & Africa Others - Market Revenue and Forecast to 2028 (US\$ Million)	
10. Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Mode of Action	
10.1 Overview	
10.2 Middle East & Africa Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)	
10.2.1 Middle East & Africa: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US\$ Million)	
10.3 Inhibits Neuraminidase	
10.3.1 Overview	
10.3.2 Middle East & Africa Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US\$ Million)	
10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate	
10.4.1 Overview	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.4.2 Middle East & Africa Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US\$ Million)
- 10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)
  - 10.5.1 Overview
  - 10.5.2 Middle East & Africa Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US\$ Million)
- 10.6 Tissue Plasminogen Activator
  - 10.6.1 Overview
  - 10.6.2 Middle East & Africa Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US\$ Million)
- 10.7 Inhibits Glucosylceramide Synthase
  - 10.7.1 Overview
  - 10.7.2 Middle East & Africa Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US\$ Million)
- 10.8 Interleukin 1 And 2 And 3
  - 10.8.1 Overview
  - 10.8.2 Middle East & Africa Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US\$ Million)
- 10.9 Beta And Gamma Interferons
  - 10.9.1 Overview
  - 10.9.2 Middle East & Africa Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US\$ Million)
- 10.10 Others
  - 10.10.1 Overview
  - 10.10.2 Middle East & Africa Others- Market Revenue And Forecasts To 2028 (US\$ Million)
- 11. Middle East & Africa Glycomic Therapeutics Market Revenue and Forecasts to 2028 - Country Analysis
  - 11.1 Middle East & Africa: Glycomic Therapeutics Market
    - 11.1.1 Overview
      - 11.1.2 Middle East & Africa: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
        - 11.1.2.1 Saudi Arabia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
          - 11.1.2.1.1 Overview
            - 11.1.2.1.2 Saudi Arabia: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)
            - 11.1.2.1.3 Saudi Arabia: Glycomic Therapeutics Market, by Class, 2019-2028 (US\$ Million)
            - 11.1.2.1.4 Saudi Arabia: Glycomic Therapeutics Market, by Structure, 2019-2028 (US\$ Million)
              - 11.1.2.1.4.1 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US\$ Million)
              - 11.1.2.1.4.2 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US\$ Million)
              - 11.1.2.1.4.3 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US\$ Million)
              - 11.1.2.1.4.4 Saudi Arabia: Glycomic Therapeutics Market, by Others, 2019-2028 (US\$ Million)
            - 11.1.2.1.5 Saudi Arabia: Glycomic Therapeutics Market, by Indication, 2019-2028 (US\$ Million)
            - 11.1.2.1.6 Saudi Arabia: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US\$ Million)
          - 11.1.2.2 UAE: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
            - 11.1.2.2.1 Overview
              - 11.1.2.2.2 UAE: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)
              - 11.1.2.2.3 UAE: Glycomic Therapeutics Market, by Class, 2019-2028 (US\$ Million)
              - 11.1.2.2.4 UAE: Glycomic Therapeutics Market, by Structure, 2019-2028 (US\$ Million)
                - 11.1.2.2.4.1 UAE: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US\$ Million)
                - 11.1.2.2.4.2 UAE: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US\$ Million)
                - 11.1.2.2.4.3 UAE: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US\$ Million)
                - 11.1.2.2.4.4 UAE: Glycomic Therapeutics Market, by Others, 2019-2028 (US\$ Million)
              - 11.1.2.2.5 UAE: Glycomic Therapeutics Market, by Indication, 2019-2028 (US\$ Million)
              - 11.1.2.2.6 UAE: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.1.2.3 South Africa: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
  - 11.1.2.3.1 Overview
  - 11.1.2.3.2 South Africa: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.2.3.3 South Africa: Glycomic Therapeutics Market, by Class, 2019-2028 (US\$ Million)
  - 11.1.2.3.4 South Africa: Glycomic Therapeutics Market, by Structure, 2019-2028 (US\$ Million)
    - 11.1.2.3.4.1 South Africa: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US\$ Million)
    - 11.1.2.3.4.2 South Africa: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US\$ Million)
    - 11.1.2.3.4.3 South Africa: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US\$ Million)
    - 11.1.2.3.4.4 South Africa: Glycomic Therapeutics Market, by Others, 2019-2028 (US\$ Million)
  - 11.1.2.3.5 South Africa: Glycomic Therapeutics Market, by Indication, 2019-2028 (US\$ Million)
  - 11.1.2.3.6 South Africa: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US\$ Million)
- 11.1.2.4 Rest of Middle East and Africa: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
  - 11.1.2.4.1 Overview
  - 11.1.2.4.2 Rest of MEA: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.2.4.3 Rest of MEA: Glycomic Therapeutics Market, by Class, 2019-2028 (US\$ Million)
  - 11.1.2.4.4 Rest of MEA: Glycomic Therapeutics Market, by Structure, 2019-2028 (US\$ Million)
    - 11.1.2.4.4.1 Rest of MEA: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US\$ Million)
    - 11.1.2.4.4.2 Rest of MEA: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US\$ Million)
    - 11.1.2.4.4.3 Rest of MEA: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US\$ Million)
    - 11.1.2.4.4.4 Rest of MEA: Glycomic Therapeutics Market, by Others, 2019-2028 (US\$ Million)
  - 11.1.2.4.5 Rest of MEA: Glycomic Therapeutics Market, by Indication, 2019-2028 (US\$ Million)
  - 11.1.2.4.6 Rest of MEA: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US\$ Million)
- 12. Middle East & Africa Glycomic Therapeutics Market -Industry Landscape
  - 12.1 Overview
  - 12.2 Growth Strategies in the Glycomic Therapeutics Market (%)
  - 12.3 Organic Developments
    - 12.3.1 Overview
  - 12.4 Inorganic Developments
    - 12.4.1 Overview
- 13. Company Profiles
  - 13.1 Protalix Biotherapeutics
    - 13.1.1 Key Facts
    - 13.1.2 Business Description
    - 13.1.3 Products and Services
    - 13.1.4 Financial Overview
    - 13.1.5 SWOT Analysis
    - 13.1.6 Key Developments
  - 13.2 BioMarin Pharmaceutical Inc.
    - 13.2.1 Key Facts
    - 13.2.2 Business Description
    - 13.2.3 Products and Services
    - 13.2.4 Financial Overview
    - 13.2.5 SWOT Analysis
    - 13.2.6 Key Developments
  - 13.3 Genzyme Corporation (Sanofi)
    - 13.3.1 Key Facts
    - 13.3.2 Business Description

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Bayer AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 GlaxoSmithKline plc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 F. Hoffmann-La Roche Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms in Glycomic Therapeutics Market

**Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]**

Market Report | 2022-11-18 | 197 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to [support@scotts-international.com](mailto:support@scotts-international.com)


**ORDER FORM:**

Select license	License	Price
----------------	---------	-------

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)




Single User Price
-------------------

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)






Site Price
------------












**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)





**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)


**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)







**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.  
☐\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-08"/>
		Signature	<input type="text"/>